


Spinraza-Zolgensma Combination Well-tolerated in Children with SMA Type 1, Study Shows
by Victorian Adan | Aug 27, 2020 | Genetic Counselor Resource Pages, Genetic Counselors News, Just Published, Neurology News, News, Pediatricians News, slider
Combining Spinraza (nusinersen) with the gene therapy Zolgensma (onasemnogene abeparvovec-xioi) is generally well-tolerated and sustains motor improvements in children with spinal muscular atrophy (SMA) type 1, according to a case series study. The data, which...Video
SMA – Core Topics
- What is SMA?
- Types of SMA
- Spinal Muscular Atrophy Type 0
- Spinal Muscular Atrophy Type 1
- Spinal Muscular Atrophy Type 2
- Spinal Muscular Atrophy Type 3
- Spinal Muscular Atrophy Type 4
- Rare Forms of SMA
- SMN1-negative variants resembling Adult Onset SMA
- SMN1-negative variants resembling Infantile Onset SMA
- SMN1-negative variants resembling Childhood Onset SMA
- Pre-Symptomatic Intervention
- Genetics and Epidemiology
- Signs and Symptoms
- Comorbid Conditions
- Diagnosis
- Differential Diagnosis
- Disease-Modifying Therapy
- Testing
- Orthopedic Surgery
- Discussing Clinical Trials
- Respiratory Care
- Physical Therapy
- Home Modifications
- Feeding, GERD, and GI Issues
- Delayed Growth
- School and Educational Concerns
- Maximizing Quality of Life
- Assistive Devices
- Speech Therapy
- Occupational Therapy
- Nutrition
- Medical Transportation and Hospitalization
- Pain Management
- Patient & Caregiver Concerns
- Prognosis
- Palliative Care
HCP — SMA News Today
BioNews Services, LLC
3 W Garden St
Suite 354
Pensacola, FL 32502
Email: [email protected]
Phone: 1-800-936-1363